QURE logo

uniQure N.V. (QURE)

$20.78

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on QURE

Market cap

$1.46B

EPS

-3.52

P/E ratio

--

Price to sales

83.92

Dividend yield

--

Beta

1.146776

Price on QURE

Previous close

$21.88

Today's open

$21.76

Day's range

$20.52 - $21.76

52 week range

$8.73 - $51.72

Profile about QURE

CEO

Matthew Kapusta

Employees

221

Headquarters

Amsterdam,

Exchange

Nasdaq Global Select

Shares outstanding

70138860

Issue type

Common Stock

QURE industries and sectors

Healthcare

Biotechnology & Life Sciences

News on QURE

uniQure: A Breakthrough In Huntington's, With A Market Too Large To Ignore

The FDA reversed its support for natural-history controls, demanded a sham-controlled trial, then reversed course again, delaying progress for months while Huntington's patients continued suffering irreversible decline. The latest Enroll-HD comparator is biased toward much slower-progressing Huntington's disease patients, as faster progressors are dropping out of the comparator over time, potentially materially understating AMT-130's treatment benefit. High-dose AMT-130 showed 80% slowing on cUHDRS at three years and 61% on TFC at four years; the four-year primary test missed significance.

news source

Seeking Alpha • Nov 14, 2026

news preview

uniQure CEO Defends Huntington's Therapy Data, Sees Opportunity Ahead of FDA Decision

uniQure NASDAQ: QURE Chief Executive Matt Kapusta said investors are focused on regulatory risk surrounding its experimental Huntington's disease therapy, AMT-130, but may be underestimating the need for treatment and the potential commercial opportunity.

news source

MarketBeat • Nov 13, 2026

news preview

uniQure Prepares for Potential FDA Panel on Huntington's Gene Therapy After Priority Review Nod

uniQure NASDAQ: QURE is preparing for a potential U.S. advisory committee meeting on AMT-130, its experimental gene therapy for Huntington's disease, after regulators accepted its biologics license application for priority review, CEO Matt Kapusta said.

news source

MarketBeat • Nov 13, 2026

news preview

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure shares rally 17.5% as FDA grants Priority Review to its Huntington's disease gene therapy, but it remains to be seen if clinical and regulatory progress can sustain momentum.

news source

Zacks Investment Research • Nov 13, 2026

news preview

uniQure Q3 Earnings Call Highlights

uniQure NASDAQ: QURE said the FDA has accepted its Biologics License Application for AMT-130, an investigational treatment for Huntington's disease, and granted the application Priority Review with a target action date of May 1, 2027. The U.K. Medicines and Healthcare products Regulatory Agency has also validated the company's Marketing Authorization Application, according to management.

news source

MarketBeat • Nov 4, 2026

news preview

uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript

uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update

~ FDA granted priority review of BLA for  ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~

news source

GlobeNewsWire • Nov 4, 2026

news preview

uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates

uniQure (QURE) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $1.38 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

uniQure: The Market May Be Misreading The AMT-130 Four-Year Data (Rating Upgrade)

uniQure's stock has come under significant pressure again after the company reported mixed 4-year AMT-130 data. While measurement noise and control bias likely explain much of the disappointing results, there is now greater uncertainty around durability. I believe that uniQure's data is strong enough to support accelerated approval despite this, though.

news source

Seeking Alpha • Nov 4, 2026

news preview

Uniqure Stock Falls After Its Huntington's Gene Therapy Lands At The FDA

The FDA said Monday it will make an approval decision on Uniqure's Huntington's gene therapy by May 1. But Uniqure stock fell.

news source

Investors Business Daily • Nov 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in uniQure N.V.

Open an M1 investment account to buy and sell uniQure N.V. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in QURE on M1